Cycle and Catalent, Inc. (NYSE: CTLT) have partnered to develop 4 products that will each use Catalent’s Zydis® oral disintegrating tablet (ODT) and Zydis Ultra® technologies.
Read the press release here.
Cycle and Medherant Ltd (a spin-out company from the University of Warwick, UK) have partnered to develop products that will each use Medherant’s TEPI Patch® transdermal patch technology.
Zydis® and Zydis Ultra® are registered trademarks of R.P. Scherer Technologies, Inc., a wholly owned subsidiary of Catalent, Inc. TEPI Patch® is a registered trademark of Medherant Limited.